The right time for American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) on metastatic castration-resistant prostate cancer.
A recent study published in the Journal of Clinical Oncology links male pattern baldness with elevated risk of aggressive prostate cancer.
ALCHEMIST to screen 8,000 patients with early-stage lung cancer, randomly assigning patients with EGFR mutations or rearrangement of the ALK gene.
Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.
Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.
Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|